Healthcare provider profile · identity verified

Giovanni Lupo, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MELBOURNE, FL · NPI 1255394060

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Giovanni Lupo, MD received $792.72 in general payments during 2025 across 7 reported records.

Janssen Biotech, Inc. accounted for 18.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 6 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 514 claims for Eliquis by this doctor in 2024.

Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Xarelto by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$792.72

7 reported records · 7 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Janssen Biotech, Inc.	Unresolved — no canonical attribution shown	$149.86	18.9%	1	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$125.00	15.8%	1	2025
PharmaEssentia USA Corporation	Unresolved — no canonical attribution shown	$125.00	15.8%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$124.46	15.7%	1	2025
Daiichi Sankyo Inc.	Unresolved — no canonical attribution shown	$124.46	15.7%	1	2025
Syndax Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$123.69	15.6%	1	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$20.25	2.5%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$792.72	7

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CARVYKTI Normalized: carvykti	Drug	Janssen Biotech, Inc.	$149.86	1	2025
Source payment records 2025-07-24 · Janssen Biotech, Inc. · $149.86 · Open Payments source
RYBREVANT Normalized: rybrevant	Drug	Janssen Biotech, Inc.	$149.86	1	2025
Source payment records 2025-07-24 · Janssen Biotech, Inc. · $149.86 · Open Payments source
BESREMI Normalized: besremi	Drug	PharmaEssentia USA Corporation	$125.00	1	2025
Source payment records 2025-02-20 · PharmaEssentia USA Corporation · $125.00 · Open Payments source
REBLOZYL Normalized: reblozyl	Biological	E.R. Squibb & Sons, L.L.C.	$125.00	1	2025
Source payment records 2025-10-21 · E.R. Squibb & Sons, L.L.C. · $125.00 · Open Payments source
Enhertu Normalized: enhertu	Drug	Daiichi Sankyo Inc.	$124.46	1	2025
Source payment records 2025-05-06 · Daiichi Sankyo Inc. · $124.46 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$20.25	1	2025
Source payment records 2025-02-26 · Neurocrine BioSciences, Inc. · $20.25 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	18	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	LOKELMA open payments reported associated product	CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624	Lokelma · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	514	55
Janssen Biotech, Inc. Exact reporting entity; no affiliate inference	2025	XARELTO open payments reported associated product	CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978	Xarelto · 2024 Exact normalized brand match · 1 Part D row	120	14

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	730	113
Levothyroxine Sodium	Levothyroxine Sodium	685	100
Eliquis	Apixaban	514	55
Amlodipine Besylate	Amlodipine Besylate	461	72
Pantoprazole Sodium	Pantoprazole Sodium	446	67
Potassium Chloride	Potassium Chloride	417	69
Furosemide	Furosemide	360	62
Metoprolol Tartrate	Metoprolol Tartrate	349	60
Losartan Potassium	Losartan Potassium	327	51
Trazodone Hcl	Trazodone Hcl	302	56
Metoprolol Succinate	Metoprolol Succinate	281	47
Omeprazole	Omeprazole	278	62
Lisinopril	Lisinopril	269	44
Gabapentin	Gabapentin	261	45
Memantine Hcl	Memantine Hcl	239	40
Simvastatin	Simvastatin	234	35
Tamsulosin Hcl	Tamsulosin Hcl	226	38
Donepezil Hcl	Donepezil Hcl	219	32
Famotidine	Famotidine	218	37
Quetiapine Fumarate	Quetiapine Fumarate	213	38
Mirtazapine	Mirtazapine	196	32
Escitalopram Oxalate	Escitalopram Oxalate	188	42
Metformin Hcl	Metformin Hcl	177	25
Sertraline Hcl	Sertraline Hcl	165	24
Rosuvastatin Calcium	Rosuvastatin Calcium	152	21
Duloxetine Hcl	Duloxetine Hcl	151	22
Alprazolam	Alprazolam	146	23
Jardiance	Empagliflozin	120	suppressed
Xarelto	Rivaroxaban	120	14
Carvedilol	Carvedilol	118	22
Buspirone Hcl	Buspirone Hcl	113	18
Myrbetriq	Mirabegron	111	14
Pravastatin Sodium	Pravastatin Sodium	101	15
Spironolactone	Spironolactone	101	18
Cefuroxime	Cefuroxime Axetil	97	42
Finasteride	Finasteride	94	18
Tramadol Hcl	Tramadol Hcl	93	21
Clopidogrel	Clopidogrel Bisulfate	92	14
Montelukast Sodium	Montelukast Sodium	83	15
Amiodarone Hcl	Amiodarone Hcl	81	14
Latanoprost	Latanoprost	81	20
Hydrochlorothiazide	Hydrochlorothiazide	80	16
Carbidopa-Levodopa	Carbidopa/Levodopa	79	12
Allopurinol	Allopurinol	78	suppressed
Cephalexin	Cephalexin	76	43
Azithromycin	Azithromycin	75	57
Nystatin	Nystatin	72	29
Fluticasone Propionate	Fluticasone Propionate	70	25
Lactulose	Lactulose	69	18
Lorazepam	Lorazepam	68	18
Diclofenac Sodium	Diclofenac Sodium	67	19
Midodrine Hcl	Midodrine Hcl	67	17
Trimethoprim	Trimethoprim	64	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	63	suppressed
Ondansetron Hcl	Ondansetron Hcl	63	38
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	61	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	61	20
Januvia	Sitagliptin Phosphate	61	suppressed
Levetiracetam	Levetiracetam	61	11
Methenamine Hippurate	Methenamine Hippurate	60	11
Prednisone	Prednisone	60	20
Divalproex Sodium	Divalproex Sodium	59	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	suppressed
Bupropion Xl	Bupropion Hcl	58	suppressed
Hydralazine Hcl	Hydralazine Hcl	58	15
Atenolol	Atenolol	57	suppressed
Pregabalin	Pregabalin	57	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	55	40
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	55	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	54	30
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	53	suppressed
Citalopram Hbr	Citalopram Hydrobromide	52	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	51	suppressed
Tradjenta	Linagliptin	49	suppressed
Celecoxib	Celecoxib	46	suppressed
Entresto	Sacubitril/Valsartan	45	suppressed
Propranolol Hcl	Propranolol Hcl	45	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	44	suppressed
Breo Ellipta	Fluticasone/Vilanterol	44	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	44	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	43	15
Nuplazid	Pimavanserin Tartrate	43	suppressed
Valsartan	Valsartan	43	suppressed
Folic Acid	Folic Acid	41	suppressed
Oxycodone Hcl	Oxycodone Hcl	40	suppressed
Lovastatin	Lovastatin	36	suppressed
Warfarin Sodium	Warfarin Sodium	36	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	35	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	27
Raloxifene Hcl	Raloxifene Hcl	34	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	33	suppressed
Clonidine Hcl	Clonidine Hcl	32	14
Sotalol	Sotalol Hcl	32	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	31	11
Digoxin	Digoxin	31	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	18
Oxybutynin Chloride	Oxybutynin Chloride	31	suppressed
Glipizide Er	Glipizide	30	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	30	24
Primidone	Primidone	30	suppressed
Levofloxacin	Levofloxacin	29	22
Paxlovid	Nirmatrelvir/Ritonavir	29	29
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	22
Ibandronate Sodium	Ibandronate Sodium	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Ranolazine Er	Ranolazine	28	suppressed
Ursodiol	Ursodiol	28	suppressed
Acetylcysteine	Acetylcysteine	27	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	27	suppressed
Oxcarbazepine	Oxcarbazepine	27	suppressed
Rivastigmine	Rivastigmine	27	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	suppressed
Ketoconazole	Ketoconazole	26	11
Loperamide	Loperamide Hcl	26	21
Methocarbamol	Methocarbamol	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Meclizine Hcl	Meclizine Hcl	25	suppressed
Olanzapine	Olanzapine	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Timolol Maleate	Timolol Maleate	25	suppressed
Ceftriaxone	Ceftriaxone Sodium	24	14
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Glimepiride	Glimepiride	24	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	24	suppressed
Phenobarbital	Phenobarbital	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Acetic Acid	Acetic Acid	23	suppressed
Incruse Ellipta	Umeclidinium Bromide	23	suppressed
Lidocaine	Lidocaine	23	suppressed
Terazosin Hcl	Terazosin Hcl	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Ammonium Lactate	Ammonium Lactate	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	21	suppressed
Lidocaine Hcl	Lidocaine Hcl	21	13
Lubiprostone	Lubiprostone	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	21	suppressed
Glipizide	Glipizide	20	suppressed
Insulin Aspart Flexpen	Insulin Aspart	20	suppressed
Klor-Con 10	Potassium Chloride	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Multaq	Dronedarone Hcl	19	suppressed
Protonix	Pantoprazole Sodium	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	18	suppressed
Erythromycin	Erythromycin Base	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Mesalamine	Mesalamine	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Dutasteride	Dutasteride	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Cefdinir	Cefdinir	15	12
Neupro	Rotigotine	15	suppressed
Rytary	Carbidopa/Levodopa	15	suppressed
Anastrozole	Anastrozole	14	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	14	12
Mupirocin	Mupirocin	14	suppressed
Novofine Autocover	Pen Needle, Diabetic, Safety	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Rivastigmine	Rivastigmine Tartrate	14	suppressed
Tobramycin	Tobramycin	14	11
Alcohol Swabs	Alcohol Antiseptic Pads	13	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Felodipine Er	Felodipine	13	suppressed
Humulin R	Insulin Regular, Human	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Risperidone	Risperidone	13	suppressed
Scopolamine	Scopolamine	13	suppressed
Trandolapril	Trandolapril	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	12	suppressed
Bethanechol Chloride	Bethanechol Chloride	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Edarbyclor	Azilsartan Med/Chlorthalidone	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Hydroxyurea	Hydroxyurea	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Letrozole	Letrozole	12	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	12	suppressed
Lumigan	Bimatoprost	12	suppressed
Paliperidone Er	Paliperidone	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Metolazone	Metolazone	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$792.72 · 7 records	Janssen Biotech, Inc.	BESREMI, CARVYKTI, Enhertu, INGREZZA, REBLOZYL, RYBREVANT	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error